CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers

被引:274
作者
Huang, Bo
Lei, Zhang
Zhao, Jie
Gong, Wei
Liu, Jinwen
Chen, Zhenyong
Liu, Yi
Li, Dong
Yuan, Ye
Zhang, Gui-Mei
Feng, Zuo-Hua [1 ]
机构
[1] Huazhong Univ Sci & Technol, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Peoples R China
[2] Huazhong Univ Sci & Technol, Dept Gen Surg, Tongji Hosp, Wuhan 430030, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Gen Surg, Union Hosp, Wuhan 430030, Peoples R China
基金
中国国家自然科学基金;
关键词
CCL2; CCR2; MSC; migration; tumor;
D O I
10.1016/j.canlet.2006.12.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In addition to direct effect on tumor cells, the tumor-promoting activity of CCL2 has been ascribed to its role in chemoattracting tumor-associated macrophages. However it is unclear whether CCL2 also attracts other immune regulatory cells during tumor development. In this study, we confirmed the ubiquitous expression of CCR2 in myeloid suppressor cells (MSCs), a main inducer for tumor immune evasion, and identified that cancer patient-derived CCL2 mediated the migration of MSCs to tumors in vitro, which could be interdicted by antibodies neutralizing CCL2 or blocking CCR2. In mouse tumor model, the adoptively transferred CCR2(-/-) MSCs could not migrate to either tumor or spleen as efficiently as WT MSCs. The absence of CCL2/CCR2 signaling hindered both MSC migration and MSC-promoted tumor growth. Our data provide evidence that CCL2/CCR2 pathway plays a pivotal role in MSC migration, which is a novel mechanism through which CCL2 promotes tumor growth.(c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:86 / 92
页数:7
相关论文
共 20 条
[1]   Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer [J].
Almand, B ;
Clark, JI ;
Nikitina, E ;
van Beynen, J ;
English, NR ;
Knight, SC ;
Carbone, DP ;
Gabrilovich, DI .
JOURNAL OF IMMUNOLOGY, 2001, 166 (01) :678-689
[2]   Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines [J].
Arenberg, DA ;
Keane, MP ;
DiGiovine, B ;
Kunkel, SL ;
Strom, SRB ;
Burdick, MD ;
Iannettoni, MD ;
Strieter, RM .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (02) :63-70
[3]   A CHEMOATTRACTANT EXPRESSED IN HUMAN SARCOMA-CELLS (TUMOR-DERIVED CHEMOTACTIC FACTOR, TDCF) IS IDENTICAL TO MONOCYTE CHEMOATTRACTANT PROTEIN-1 MONOCYTE CHEMOTACTIC AND ACTIVATING FACTOR (MCP-1/MCAF) [J].
BOTTAZZI, B ;
COLOTTA, F ;
SICA, A ;
NOBILI, N ;
MANTOVANI, A .
INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (04) :795-797
[4]   IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice [J].
Bronte, V ;
Serafini, P ;
De Santo, C ;
Marigo, I ;
Tosello, V ;
Mazzoni, A ;
Segal, DM ;
Staib, C ;
Lowel, M ;
Sutter, G ;
Colombo, MP ;
Zanovello, P .
JOURNAL OF IMMUNOLOGY, 2003, 170 (01) :270-278
[5]   CCL2 (monocyte chemoattractant protein-1) and cancer [J].
Conti, I ;
Rollins, BJ .
SEMINARS IN CANCER BIOLOGY, 2004, 14 (03) :149-154
[6]   Mechanisms and functional significance of tumour-induced dendritic-cell defects [J].
Gabrilovich, D .
NATURE REVIEWS IMMUNOLOGY, 2004, 4 (12) :941-952
[7]   Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host [J].
Huang, B ;
Pan, PY ;
Li, QS ;
Sato, AI ;
Levy, DE ;
Bromberg, J ;
Divino, CM ;
Chen, SH .
CANCER RESEARCH, 2006, 66 (02) :1123-1131
[8]   Toll-like receptors on tumor cells facilitate evasion of immune surveillance (Publication with Expression of Concern. See vol. 79, pg. 4305, 2019) [J].
Huang, B ;
Zhao, J ;
Li, HX ;
He, KL ;
Chen, YB ;
Mayer, L ;
Unkeless, JC ;
Xiong, HB .
CANCER RESEARCH, 2005, 65 (12) :5009-5014
[9]  
Huang RC, 2002, CANCER RES, V62, P2806
[10]   Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells [J].
Kleine-Lowinski, K ;
Rheinwald, JG ;
Fichorova, RN ;
Anderson, DJ ;
Basile, J ;
Münger, K ;
Daly, CM ;
Rösl, F ;
Rollins, BJ .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (03) :407-415